维康药业(300878) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥69,775,938.28, a decrease of 65.10% compared to ¥199,953,044.93 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥9,854,658.34, representing a decline of 140.50% from a profit of ¥24,334,978.24 in the previous year[5] - The basic earnings per share for the period was -¥0.07, down 141.18% from ¥0.17 in the same period last year[5] - Net profit for the period was a loss of ¥9,706,327.17 compared to a profit of ¥24,389,323.96 in the previous period, indicating a significant downturn[18] - The company's net profit margin and future guidance were not explicitly detailed in the provided documents[12] Cash Flow and Operating Activities - The net cash flow from operating activities improved to -¥6,488,555.71, a 60.53% increase compared to -¥16,439,476.59 in the same period last year[5] - Operating cash flow net amount was a negative ¥6,488,555.71, an improvement from a negative ¥16,439,476.59 in the previous period[21] - Cash and cash equivalents at the end of the period increased to ¥259,807,484.08 from ¥225,921,021.74, showing a positive change[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,638,649,780.40, a decrease of 0.83% from ¥1,652,323,039.56 at the end of the previous year[5] - The total assets of Zhejiang Weikang Pharmaceutical Co., Ltd. as of March 31, 2025, amounted to CNY 1,638,649,780.40, a decrease from CNY 1,652,323,039.56 at the beginning of the period[14] - Total current liabilities decreased to CNY 228,091,892.00 from CNY 240,381,545.98, a reduction of about 5.1%[15] - Long-term borrowings increased to CNY 197,372,877.74 from CNY 186,619,205.86, reflecting an increase of approximately 5.7%[15] - The total equity attributable to the parent company decreased to CNY 1,147,811,901.37 from CNY 1,157,666,559.71, a decline of about 0.9%[16] Sales and Expenses - The cash received from sales of goods and services was ¥58,473,216.71, a decrease of 54.16% from ¥127,565,675.80 in the previous year[9] - Total operating revenue decreased to ¥69,775,938.28 from ¥199,953,044.93, representing a decline of approximately 65% year-over-year[17] - Total operating costs decreased to ¥79,431,824.89 from ¥173,888,443.65, a reduction of about 54% year-over-year[17] - The company reported a decrease in sales expenses to ¥30,418,191.53 from ¥52,336,889.43, a reduction of approximately 42% year-over-year[17] - Research and development expenses slightly decreased to ¥2,671,042.00 from ¥2,971,220.93, a decline of about 10% year-over-year[17] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 11,248, with the largest shareholder holding 60.89% of the shares[10] Asset Impairment and Credit Quality - The company reported a significant increase in asset impairment losses, which rose by 4354.98% to ¥1,541,958.53 compared to -¥34,612.01 in the previous year[9] - The company incurred a credit impairment loss of ¥4,867,447.87 compared to a gain of ¥4,978,010.08 in the previous period, indicating a significant shift in credit quality[18] Government Support and Investments - The company received government subsidies amounting to ¥2,060,338.52 during the reporting period[6] - The total cash inflow from investment activities was ¥44,625,315.68, a decrease from ¥250,969,467.74 in the previous period[21] Market and Product Development - There were no significant updates on new product developments or market expansions mentioned in the conference call[12] - The company did not report any mergers or acquisitions during this period[12]